Projecting future drug expenditures--2012. (Q39650889)

13 September 2017

Projecting future drug expenditures--2012. (English)

1 reference

13 September 2017

8

Glen T Schumock

1 reference

13 September 2017

James M Hoffman

1

1 reference

13 September 2017

Edward Li

2

1 reference

13 September 2017

Fred Doloresco

3

1 reference

13 September 2017

Linda Matusiak

4

1 reference

13 September 2017

Robert J Hunkler

5

1 reference

13 September 2017

Nilay D Shah

6

1 reference

13 September 2017

Lee C Vermeulen

7

1 reference

13 September 2017

1 March 2012

1 reference

American Journal of Health-System Pharmacy

13 September 2017

1 reference

13 September 2017

69

1 reference

13 September 2017

5

1 reference

13 September 2017

405-421

1 reference

Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage

13 September 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

The consensus of the Pharmacy Practice Model Summit

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Projecting future drug expenditures--2009.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

The demise of the blockbuster?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Drug-review deadlines and safety problems

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Projecting future drug expenditures--2006.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Oral rivaroxaban for symptomatic venous thromboembolism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Impact of oral direct thrombin inhibitors on anticoagulation clinics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Novel oral anticoagulants and their role in clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Role of pharmacogenomics in the management of traditional and novel oral anticoagulants

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Prasugrel versus clopidogrel in patients with acute coronary syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

31 March 2020

Invasive Breast Cancer

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Projecting future drug expenditures: 2011.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

"Pay for delay" settlements of disputes over pharmaceutical patents

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Impact of drug shortages on U.S. health systems

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

Projecting future drug expenditures--2010.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

National health spending projections through 2020: economic recovery and reform drive faster spending growth

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

ASHP guidelines on medication cost management strategies for hospitals and health systems

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110697

31 March 2020

Identifiers

DOI

10.2146/AJHP110697

1 reference

13 September 2017

1 reference